LDS/Medical Tests/Hexosaminidase A (HEXA) Gene Mutation Analysis

Hexosaminidase A (HEXA) Gene Mutation Analysis

The HEXA gene (cytogenetic location: 15q23) encodes the alpha subunit of an enzyme called beta-hexosaminidase A. The active enzyme also contains a beta subunit which is encoded by HEXB gene. This enzyme is predominantly located in the lysosome of cells of the central nervous system (brain and spinal cord) and plays a critical role in the degradation pathway of GM2 ganglioside. Over 120 mutations have been identified in the HEXA gene resulting in absence or reduced activity of the enzyme. As a result, breakdown of GM2 ganglioside is impaired and it accumulates in neurons and progressively damages the cells leading to neurodegeneration and neurological manifestations. Beta-hexosaminidase A deficiency is also called Tay-Sachs disease (TSD) (OMIM entry # 272800) or GM2 gangliosidosis.

Tay-Sachs disease is an autosomal recessive disorder with low prevalence in the general population (1 in 300,000 live births) but a considerably higher prevalence in Ashkenazi Jewish populations of 1 in 3500 live births. The mutations responsible for this disease are also more common in certain French-Canadian communities of Quebec, the Old Order Amish community in Pennsylvania, and the Cajun population of Louisiana. The disease typically manifests 3 to 6 months after birth with poor development and weak motor skills. As the disease progress, it is characterized by seizures, impaired vision and hearing, intellectual disability, and paralysis. The “Startle reaction” and “cherry-red spot” of the macula on eye examination are characteristic clinical features of this disorder. The severe infantile forms of the disease are usually fetal by early childhood. Other forms of Tay-Sachs disease (subacute and adult-onset) are rare and symptoms appears later on life.

Common mutations and alterations in the HEXA gene include 7.6kb del, c.1073+1G>A, p.Y427Ifs (c.1274_1277dup TATC), c.1421+1G>C, p.G269S (c.805G>A), alleles p.R247W (c.739C>T) and p.R249W (c.745C>T). Positive mutation results for the latter two mutations are associated with the presence of a ‘pseudo-deficiency allele’, that is, they are not associated with disease but do result in decreased activity of the enzyme. Evaluation of these common mutations in the HEXA gene will identify over 90% of disease-causing mutations in the Ashkenazi Jewish population. Sequencing of the entire HEXA gene can detect other less common disease-causing mutations.

  • Diagnosis confirmation of Tay-Sachs disease
  • Useful to confirm common pathogenic and pseudo-deficiency HEXA variants in the Ashkenazi Jewish population
  • Carrier screening in the individuals with a family history of Tay-Sachs disease
  • Useful for prenatal diagnosis of Tay-Sachs disease in at-risk families
  • Useful in the screening of Tay-Sachs disease in the Ashkenazi Jewish population
  • If mutations detected (pathogenic variants) are heterozygous indicates carrier status
  • If mutations detected (pathogenic variants) are homozygous or compound heterozygous indicates disease

No reportable variants identified (Negative for mutations analyzed)

Allele specific primer extension real-time PCR (ARMS), Sanger sequencing, Next generation sequencing.

Whole blood (EDTA), Amniotic fluid, Amniocyte culture, Chorionic villus sampling.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
HEXA Gene Sequencing, Hexosaminidase A percentage and total hexosaminidase in plasma and leukocytes.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login